Chemical compound
Globalagliatin Other names SY-004 Legal status
(1R ,2S )-2-Cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N -[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide
CAS Number PubChem CID Formula C 28 H 37 N 3 O 3 S 3 Molar mass 559.80 g·mol−1
Globalagliatin (SY-004 ) is a glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes.[1] [2] [3]
^ Zhao, Yuqing; Xie, Lijun; Zhang, Hongwen; Zhou, Sufeng; Liu, Yun; Chen, Juan; Wang, Lu; Wang, Libin; Zhuo, Lang; Wang, Yarong; Ou, Ning; Shao, Feng (February 2022). "Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study". Clinical Therapeutics . 44 (2): 269–281. doi:10.1016/j.clinthera.2021.12.009. PMID 35093240. S2CID 246416557.
^ Zheng, Shuai; Shao, Feng; Ding, Yu; Fu, Zhenzhen; Fu, Qi; Ding, Sijia; Xie, Lijun; Chen, Juan; Zhou, Sufeng; Zhang, Hongwen; Zhou, Hongwen; Chen, Yang; Sun, Caixia; Zhu, Jing; Zheng, Xuqin; Yang, Tao (December 2020). "Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study". Clinical Drug Investigation . 40 (12): 1155–1166. doi:10.1007/s40261-020-00971-x. PMID 33125674. S2CID 225983121.
^ Yang, Wenjia; Wu, Han; Cai, Xiaoling; Lin, Chu; Jiao, Ruoyang; Ji, Linong (8 May 2023). "Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis". Frontiers in Endocrinology . 14 . doi:10.3389/fendo.2023.1175198 . PMC 10200948 . PMID 37223016.